Loading
A phase 2 trial of SSGJ-706, Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Shenyang Sunshine Pharmaceutical Co., LTD., now recruiting.
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients is a phase 2 interventional study registered as NCT07171606 by Shenyang Sunshine Pharmaceutical Co., LTD., with 240 participants planned, started 2025-10-24 and due to reach its primary completion in 2026-08-31. Interventions recorded: SSGJ-706, pemetrexed /carboplatin, Carboplatin/Paclitaxel and PD-1 Inhibitor + Chemotherapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares 3SBio and the tag pipeline.
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/